MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, WGSWW had $10,756K increase in cash & cash equivalents over the period. $21,699K in free cash flow.

Cash Flow Overview

Change in Cash
$10,756K
Free Cash flow
$21,699K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-3,355
Depreciation and amortization expense
18,343
Stock-based compensation expense
22,382
Change in fair value of financial liabilities
2,320
Deferred tax expense (benefit)
448
Provision for excess and obsolete inventory
152
Legal reserves
-810
Change in third party payor reserves
-8,746
Other
2,382
Accounts receivable
22,799
Inventory
72
Accounts payable and accrued expenses
5,185
Other assets and liabilities
-1,827
Net cash provided by (used in) operating activities
36,369
Acquisition of business, net of cash acquired
33,195
Purchases of property and equipment
14,670
Purchases of marketable securities
36,535
Proceeds from sales of marketable securities
0
Proceeds from maturities of marketable securities
33,955
Net cash used in investing activities
-50,445
Proceeds from offerings, net of issuance costs
25,568
Proceeds from issuance of common stock pursuant to employee stock purchase plan
1,262
Exercise of stock options
982
Long-term debt principal payments
906
Finance lease principal payments
2,074
Net cash provided by financing activities
24,832
Net increase (decrease) in cash, cash equivalents and restricted cash
10,756
Cash and cash equivalents at beginning of period
86,202
Cash and cash equivalents at end of period
96,958
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

GeneDx Holdings Corp. (WGSWW)

GeneDx Holdings Corp. (WGSWW)